Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes
Andrew F. Ziolkowski, Sarah K. Popp, Craig Freeman, Christopher R. Parish, Charmaine J. Simeonovic
Andrew F. Ziolkowski, Sarah K. Popp, Craig Freeman, Christopher R. Parish, Charmaine J. Simeonovic
View: Text | PDF
Research Article Metabolism

Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes

  • Text
  • PDF
Abstract

The autoimmune type 1 diabetes (T1D) that arises spontaneously in NOD mice is considered to be a model of T1D in humans. It is characterized by the invasion of pancreatic islets by mononuclear cells (MNCs), which ultimately leads to destruction of insulin-producing β cells. Although T cell dependent, the molecular mechanisms triggering β cell death have not been fully elucidated. Here, we report that a glycosaminoglycan, heparan sulfate (HS), is expressed at extraordinarily high levels within mouse islets and is essential for β cell survival. In vitro, β cells rapidly lost their HS and died. β Cell death was prevented by HS replacement, a treatment that also rendered the β cells resistant to damage from ROS. In vivo, autoimmune destruction of islets in NOD mice was associated with production of catalytically active heparanase, an HS-degrading enzyme, by islet-infiltrating MNCs and loss of islet HS. Furthermore, in vivo treatment with the heparanase inhibitor PI-88 preserved intraislet HS and protected NOD mice from T1D. Our results identified HS as a critical molecular requirement for islet β cell survival and HS degradation as a mechanism for β cell destruction. Our findings suggest that preservation of islet HS could be a therapeutic strategy for preventing T1D.

Authors

Andrew F. Ziolkowski, Sarah K. Popp, Craig Freeman, Christopher R. Parish, Charmaine J. Simeonovic

×

Figure 1

HS is highly expressed within pancreatic islets in situ, and HS loss in vitro correlates with β cell death.

Options: View larger image (or click on image) Download as PowerPoint
HS is highly expressed within pancreatic islets in situ, and HS loss in ...
(A) Detection of HS in NOD/SCID pancreatic islets in situ by Alcian blue histochemistry and immunohistochemistry using HepSS-1 anti-HS mAb. No background staining with isotype control mouse IgM was observed. Scale bars: 50 μm. (B) Intra-islet HS content (quantified by Image J with Color Deconvolution plugin) showed that the area of intraislet staining with Alcian blue was significantly higher in islets in situ (n = 50) than after isolation (n = 45; P < 0.0001). (C) Isolated BALB/c islet showing loss of intraislet HS by Alcian blue staining. Scale bar: 50 μm. (D) Intracellular HS staining was further reduced in BALB/c islet β cells during culture, as demonstrated by FACS staining using HepSS-1 (anti-HSlo; blue histogram) and 10E4 (anti-HShi; pink histogram) mAbs or an isotype control IgM (green histogram); black histogram denotes islet cell autofluorescence. Loss of β cell viability after culture for 2 days, as measured by Sytox green uptake (dead/dying cells), is shown at right. SSC-W, side scatter width. (E) Loss of intracellular HShi and HSlo and increase of cell surface HShi and HSlo was seen in β cells cultured for 2 days. *P = 0.0022; #P < 0.0001; **P = 0.0225; ##P = 0.0202. (F) Loss of intracellular HS during culture for 2 days, as in E, correlated with a significant increase in percent Sytox green+ β cells (P < 0.0001). Data are mean ± SEM (n = 6).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts